Yves Agid | Academic Influence

Yves Agid's AcademicInfluence.com Rankings

Yves Agid

Philosophy

#2058

World Rank

#3594

Historical Rank

Logic

#677

World Rank

#1181

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Yves Agid's Degrees

Doctorate Neurology Université Paris Cité

Why Is Yves Agid Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Yves Agid is a neurologist, neuropsychiatrist, cell biologist, neurochemist, academician, university professor, hospital doctor, researcher in biology and scientist specializing in neurosciences. Early life and education Yves Agid is the son of university professor Rene Agid and Swedish artist painter Sylvia Stave. Rene Agid was a close friend of Romain Gary. The latter dedicated his novel The Promise at Dawn to Rene and Sylvia Agid.

(See a Problem?)

Yves Agid's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (2382)
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. (1999) (1512)
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease (1989) (1392)
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease (1988) (1221)
Association between early-onset Parkinson's disease and mutations in the parkin gene. (2000) (1192)
Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease (1989) (1111)
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia (1994) (1093)
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. (1997) (1038)
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. (2005) (1030)
Clinical and genetic abnormalities in patients with Friedreich's ataxia. (1996) (981)
Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. (2005) (979)
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. (1991) (976)
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy (2012) (934)
Neurostimulation for Parkinson's disease with early motor complications. (2013) (920)
Partially overlapping neural networks for real and imagined hand movements. (2000) (901)
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease (2010) (885)
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease (2004) (864)
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats (1996) (853)
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. (1999) (800)
The Mental Representation of Hand Movements After Parietal Cortex Damage (1996) (796)
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion (1997) (741)
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease (1983) (719)
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. (1997) (675)
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. (2000) (673)
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. (1999) (668)
Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias (1995) (667)
Cortical control of reflexive visually-guided saccades. (1991) (620)
Nitric oxide synthase and neuronal vulnerability in parkinson's disease (1996) (589)
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease (1994) (589)
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. (2004) (546)
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. (1999) (528)
Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis (1991) (517)
Parkinson’s disease and sleepiness: An integral part of PD (2002) (507)
Parkinson's disease: pathophysiology (1991) (506)
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form (1995) (484)
INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN (1987) (470)
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. (2008) (452)
Glutathione peroxidase, glial cells and Parkinson's disease (1993) (437)
Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior (2007) (418)
Spinocerebellar ataxia 3 and machado‐joseph disease: Clinical, molecular, and neuropathological features (1996) (414)
Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up (2005) (402)
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. (2000) (400)
Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease (2010) (400)
Clinical predictive factors of subthalamic stimulation in Parkinson's disease. (2002) (396)
Nerve growth factor (NGF) in the rat CNS: Absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra (1979) (396)
FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells (1999) (388)
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: A consecutive series of 62 patients (1999) (388)
Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study (2007) (378)
Transient acute depression induced by high-frequency deep-brain stimulation. (1999) (374)
Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. (1973) (351)
Tourette’s syndrome and deep brain stimulation (2005) (343)
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (337)
Compulsions, Parkinson's disease, and stimulation (2002) (333)
Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s disease (2000) (326)
Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. (1993) (323)
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. (1998) (316)
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. (1998) (314)
A three-dimensional, histological and deformable atlas of the human basal ganglia. I. Atlas construction based on immunohistochemical and MRI data (2007) (311)
Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease (1986) (306)
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study (2008) (305)
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. (2003) (301)
Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. (1996) (299)
Accuracy of the Clinical Diagnosis of Corticobasal Degeneration (1997) (298)
Neurosurgery in Parkinson disease (2006) (297)
Restoration of normal motor control in Parkinson's disease during REM sleep. (2007) (297)
Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. (1999) (297)
How much phenotypic variation can be attributed to parkin genotype? (2003) (296)
Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23–24.1 (1993) (290)
Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study (2009) (288)
Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states (1997) (287)
Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions? (1987) (287)
Pallidal stimulation for Parkinson's disease (1997) (283)
Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation (2000) (278)
Striatal dopamine deficiency in parkinson's disease: Role of aging (1989) (275)
Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). (1998) (273)
Congruent unilateral impairments for real and imagined hand movements (1995) (271)
Eye movements in parkinsonian syndromes (1994) (269)
Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis (2001) (268)
Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia (1982) (261)
Decreased Ferritin Levels in Brain in Parkinson's Disease (1990) (259)
Hallucinations, REM sleep, and Parkinson’s disease (2000) (258)
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation (2006) (255)
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. (1994) (253)
Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. (1997) (252)
Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. (1996) (247)
Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy (1991) (245)
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. (2010) (244)
Memory disorders in probable Alzheimer's disease: the role of hippocampal atrophy as shown with MRI. (1995) (244)
Internal pallidal and thalamic stimulation in patients with Tourette syndrome. (2008) (243)
Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. (1997) (241)
Tourette syndrome deep brain stimulation: A review and updated recommendations (2015) (238)
Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. (1985) (235)
Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology (1994) (234)
Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system (1975) (234)
Behavioural disorders, Parkinson's disease and subthalamic stimulation (2002) (233)
Dopaminergic and cholinergic lesions in progressive supranuclear palsy (1985) (232)
Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. (1998) (228)
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. (1984) (227)
Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. (2000) (222)
How can drug discovery for psychiatric disorders be improved? (2007) (219)
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. (1999) (218)
Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? (1992) (216)
Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease (1993) (216)
The neuropsychological pattern of corticobasal degeneration (1995) (213)
Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom (2008) (212)
Localization of stimulating electrodes in patients with Parkinson disease by using a three-dimensional atlas-magnetic resonance imaging coregistration method. (2003) (211)
Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease (2003) (205)
Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. (1990) (202)
Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. (1995) (201)
Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients. (2004) (201)
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. (1997) (200)
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? (1989) (197)
REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. (2005) (197)
Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements (2000) (196)
Blood vessels change in the mesencephalon of patients with Parkinson's disease (1999) (194)
Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. (2004) (191)
G2019S LRRK2 mutation in French and North African families with Parkinson's disease (2005) (189)
LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASE (1986) (189)
Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? (2000) (187)
Ceramide Induces Apoptosis in Cultured Mesencephalic Neurons (1996) (187)
Dopamine deficiency in the cerebral cortex in Parkinson disease (1982) (186)
A subcortico-cortical cholinergic system is affected in Parkinson's disease (1983) (184)
Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism (1998) (181)
Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study. (2004) (181)
A Selective Impairment of Hand Posture for Object Utilization in Apraxia (1995) (177)
Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so? (2006) (176)
Mitochondrial Free Radical Signal in Ceramide‐Dependent Apoptosis: A Putative Mechanism for Neuronal Death in Parkinson's Disease (1997) (175)
Continuous and intermittent levodopa differentially affect basal ganglia function (1989) (173)
Somatostatin and dementia in Parkinson's disease (1983) (170)
Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment (1989) (167)
Improvement of sleep architecture in PD with subthalamic nucleus stimulation (2000) (167)
Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. (1993) (167)
An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease (1999) (167)
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations (1998) (165)
Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease (2000) (165)
Is the subthalamic nucleus hypointense on T2-weighted images? A correlation study using MR imaging and stereotactic atlas data. (2004) (163)
Selective Impairments in Managerial Knowledge Following Pre-Frontal Cortex Damage (1995) (163)
Consequences of Nigrostriatal Denervation on the Functioning of the Basal Ganglia in Human and Nonhuman Primates: An In Situ Hybridization Study of Cytochrome Oxidase Subunit I mRNA (1997) (162)
Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. (1988) (162)
Biochemistry of Parkinson's disease 28 years later: A critical review (1989) (161)
Labeled wheat germ agglutinin (WGA) as a new, highly sensitive retrograde tracer in the rat brain hippocampal system (1978) (160)
Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. (1997) (159)
Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. (1995) (158)
Aggressive behavior induced by intraoperative stimulation in the triangle of Sano (2002) (157)
Dopaminergic neurons degenerate by apoptosis in Parkinson's disease (1999) (156)
Cholinergic‐dependent cognitive deficits in Parkinson's disease (1987) (156)
The gene for autosomal dominant cerebellar ataxia with pigmentary macular dystrophy maps to chromosome 3p12–p21.1 (1995) (156)
Levodopa: Is toxicity a myth? (1998) (156)
Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. (1973) (155)
Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease (2001) (154)
Parkinson’s disease with camptocormia (2006) (154)
Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains (1983) (152)
Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat (1985) (152)
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. (2006) (151)
Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in parkinson's disease: An in situ hybridization study (1990) (150)
Neuronal vulnerability in Parkinson's disease. (1997) (149)
Nuclear translocation of NF‐κB in cholinergic neurons of patients with Alzheimer's disease (1997) (147)
Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? (1996) (145)
Differences in tyrosine hydroxylase-like immunoreactivity characterize the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity. (1987) (144)
Mitochondrial function and parental sex effect in Huntington's disease (1990) (144)
Cortical control of memory-guided saccades in man (2004) (144)
Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers (1998) (143)
Impaired simultaneous cognitive task performance in Parkinson's disease (1994) (143)
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. (1997) (143)
Long‐term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease (2009) (142)
Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. (2009) (140)
Confusion, dementia and anticholinergics in Parkinson's disease. (1982) (140)
Preservation of midbrain catecholaminergic neurons in very old human subjects. (2000) (138)
Effects of anterior cingulate cortex lesions on ocular saccades in humans (1998) (137)
Biochemical neuropathology of Parkinson's disease. (1984) (137)
Are dopaminergic neurons selectively vulnerable to Parkinson's disease? (1993) (136)
Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum (1995) (134)
Neurosurgery at an earlier stage of Parkinson disease (2007) (134)
Encoding of Sequence and Boundaries of Scripts Following Prefrontal Lesions (1996) (134)
Optimal target localization for subthalamic stimulation in patients with Parkinson disease (2014) (133)
Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases (1994) (133)
Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p. (1994) (132)
Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. (1994) (132)
Foot, hand, face and eye representation in the human striatum. (2003) (132)
Delayed response tasks in basal ganglia lesions in man: Further evidence for a striato-frontal cooperation in behavioural adaptation (1996) (132)
Cholinergic deficiency and frontal dysfunction in Parkinson's disease (1990) (132)
Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease. (2008) (131)
Tremor and idiopathic dystonia (1991) (131)
Injection of 6-hydroxydopamine in the substantia nigra of the rat. I. Morphological study. (1973) (131)
Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? (1990) (130)
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. (2013) (129)
The nigrostriatal system in Parkinson's disease. (1990) (127)
Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system (1976) (126)
Distinct prefrontal activations in processing sequence at the sentence and script level: An fMRI study (1999) (126)
Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease (2004) (124)
Clinical and molecular features of spinocerebellar ataxia type 6 (1997) (124)
Explicit Memory, Procedural Learning and Lexical Priming in Alzheimer's Disease (1994) (123)
Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy (2009) (122)
The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. (1996) (120)
Does levodopa aggravate Parkinson's disease? (1988) (118)
A three-dimensional histological atlas of the human basal ganglia. II. Atlas deformation strategy and evaluation in deep brain stimulation for Parkinson disease. (2009) (118)
Clinical characteristics and topography of lesions in movement disorders due to thalamic lesions (2001) (117)
Age‐induced cognitive disturbances in Parkinson's disease (1990) (116)
Clinical, electrophysiologic, and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletion (1995) (116)
Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. (2001) (115)
Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. (1996) (114)
Subthalamic stimulation in Parkinson disease: behavior and social adaptation. (2006) (114)
Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease (1986) (114)
Progressive supranuclear palsy: anatomoclinical and biochemical considerations. (1987) (113)
Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits (2013) (113)
Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson disease. (2004) (112)
Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson’s disease? (2005) (112)
Subthalamic stimulation in Parkinson disease: with or without anesthesia? (2004) (112)
Functional mapping of the human globus pallidus: contrasting effect of stimulation in the internal and external pallidum in Parkinson’s disease (2000) (111)
Sequencing of the α-Synuclein Gene in a Large Series of Cases of Familial Parkinson's Disease Fails to Reveal any Further Mutations (1998) (110)
Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson’s disease cases (1996) (110)
Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy (1986) (109)
CCK-8-immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients (1982) (109)
Association study between iron-related genes polymorphisms and Parkinson's disease (2002) (109)
Levodopa-induced dyskinesias are improved by fluoxetine (1995) (108)
Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. (1985) (107)
Delayed response tasks and prefrontal lesions in man—Evidence for self generated patterns of behaviour with poor environmental modulation (1993) (107)
Peptides and Parkinson's disease (1985) (107)
BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASE (1979) (107)
Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? (1993) (106)
Dopaminergic nerve endings in the neostriatum of the rat—1. Identification by intracerebral injections of 5-hydroxydopamine (1978) (105)
Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: A cytochrome oxidase histochemistry study (1996) (105)
Distribution of Specific High‐Affinity Binding Sites for [3H]Imipramine in Human Brain (1981) (105)
Pathology of Symptomatic Tremors (2008) (105)
Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK (2003) (104)
Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's disease (2002) (103)
Repetitive Behaviours in Patients with Gilles de la Tourette Syndrome: Tics, Compulsions, or Both? (2010) (103)
Marked phenotypic heterogeneity associated with expansion of a CAG repeat sequence at the spinocerebellar ataxia 3/Machado-Joseph disease locus. (1995) (102)
Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. (1996) (101)
Metabolic effects of nigrostriatal denervation in basal ganglia (2000) (101)
Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. (1984) (100)
Adrenergic receptors in Parkinson's disease (1984) (99)
Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? (1994) (98)
Distinct Frontal Regions for Processing Sentence Syntax and Story Grammar (1998) (97)
Subthalamic stimulation in Parkinson disease: intraoperative predictive factors. (2003) (97)
Striatopallidal and thalamic dystonia. A magnetic resonance imaging anatomoclinical study. (1996) (97)
Mesencephalic cholinergic nuclei in progressive supranuclear palsy (1991) (95)
Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra (1996) (95)
Enkephalin Dipeptidyl Carboxypeptidase (Enkephalinase) Activity: Selective Radioassay, Properties, and Regional Distribution in Human Brain (1982) (93)
Changes in neostriatal DA metabolism after carbachol or atropine microinjections into the substantia nigra. (1974) (93)
Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET (1992) (93)
Temporal limits of spatial working memory in humans (1998) (92)
Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD (2000) (92)
Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum (1996) (92)
Eye movement abnormalities correlate with genotype in autosomal dominant cerebellar ataxia type I (1998) (91)
Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France (1996) (90)
Acute effects of morphine on dopamine synthesis and release and tyrosine metabolism in the rat striatum. (1973) (90)
[3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain (1988) (90)
Preservation of cognitive function in dystonia treated by pallidal stimulation (2006) (90)
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
Tyrosine hydroxylase and methionine-enkephalin in the human mesencephalon Immunocytochemical localization and relationships (1983) (90)
Dopaminergic cell group A8 in the monkey: Anatomical organization and projections to the striatum (1999) (89)
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. (1978) (89)
Improvement of memory guided saccades in parkinsonian patients by high frequency subthalamic nucleus stimulation (2000) (88)
Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain (1995) (88)
Inhibitory influence of the nigrostriatal dopamine system on the striatal cholinergic neurons in the rat (1975) (88)
Low-dose clozapine improves dyskinesias in Parkinson's disease (1997) (87)
D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy (1988) (86)
Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain (1983) (86)
[3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. (1988) (86)
Analysis of the SCAI CAG repeat in a large number of families with dominant ataxia: Clinical and molecular correlations (1995) (86)
Are (CTG)n expansions at the SCA8 locus rare polymorphisms? (2000) (86)
Biochemistry of the hypothalamus in Parkinson's disease (1984) (86)
Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease. (1989) (85)
New mutations in protein kinase Cγ associated with spinocerebellar ataxia type 14 (2005) (85)
Choline acetyltransferase activity and [ 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions (1990) (85)
Dopamine, tremor, and Parkinson's disease (1992) (84)
Expression of glutamate receptors in the human and rat basal ganglia: Effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in parkinson's disease and rat with 6‐OHDA lesion (1996) (84)
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial (2018) (84)
A multidisciplinary study of patients with early-onset PD with and without parkin mutations (2009) (84)
Incubation period of Creutzfeldt–Jakob disease in human growth hormone recipients in France (1999) (84)
Chronic thalamic stimulation with three-dimensional MR stereotactic guidance. (1997) (83)
Progressive supranuclear palsy : clinical and research approaches (1992) (83)
Parkinson's disease: decreased density of 3H-imipramine and 3H- paroxetine binding sites in putamen (1986) (82)
Lateral visually-guided saccades in progressive supranuclear palsy. (1989) (81)
Distribution of monoaminergic, cholinergic, and GABAergic markers in the human cerebral cortex (1989) (81)
Gait and balance disorders in Parkinson's disease: Impaired active braking of the fall of centre of gravity (2009) (81)
An immunocytochemical study on the distribution of two G-protein-gated inward rectifier potassium channels (GIRK2 and GIRK4) in the adult rat brain (1997) (80)
More missense in amyloid gene (1992) (80)
Mental and Behavioral Dysfunction in Movement Disorders (2003) (80)
Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE (2011) (80)
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial (2011) (80)
The phenotype of “pure” autosomal dominant spastic paraplegia (1994) (79)
Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. (1985) (78)
Striatal dopamine D2 receptors in tardive dyskinesia: PET study. (1989) (78)
Superoxide dismutase and Parkinson's disease (1990) (78)
The α‐synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases (1998) (78)
Autoradiographic localization of glucocorticosteroid and progesterone binding sites in the human post-mortem brain. (1986) (77)
Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study. (1992) (77)
Memory for spatial location is affected in Parkinson's disease (1996) (77)
Genetic complexity and Parkinson's disease. (1997) (77)
Unawareness of naps in Parkinson’s disease and in disorders with excessive daytime sleepiness (2003) (76)
A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years. (1996) (76)
Retrograde axonal transport of125I-tetanus toxin as a too for tracing fiber connections in the central nervous system; connections of the rostral part of the rat neostriatum (1977) (76)
Confirmation of linkage of Friedreich ataxia to chromosome 9 and identification of a new closely linked marker. (1989) (75)
Decreased TrkA Gene Expression in Cholinergic Neurons of the Striatum and Basal Forebrain of Patients with Alzheimer's Disease (1997) (75)
Screening for proteins with polyglutamine expansions in autosomal dominant cerebellar ataxias. (1996) (75)
Dopaminergic nerve endings in the neostriatum of the rat—2. Radioautographic study following local micro-injections of tritiated dopamine (1978) (74)
Biochemical substrates of mental disturbances in Parkinson's disease. (1984) (73)
Distribution of ataxin-7 in normal human brain and retina. (2000) (73)
Testing cognition may contribute to the diagnosis of movement disorders (1996) (73)
Characterization and autoradiographic distribution of neurotensin binding sites in the human brain (1985) (72)
Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease (1993) (72)
Progressive supranuclear palsy: a clinicopathological study of 21 cases (1996) (72)
Subthalamic stimulation and neuronal activity in the substantia nigra in Parkinson's disease. (2007) (71)
Acute and Long-Term Administration of Anticholinergics in Parkinson's Disease: Specific Effects on the Subcortico-Frontal Syndrome (1999) (71)
Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes (1996) (71)
Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease (1985) (71)
Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? (1996) (71)
Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease (1989) (70)
Charcot‐Marie‐Tooth disease with intermediate motor nerve conduction velocities: Characterization of 14 C×32 mutations in 35 families (1997) (70)
Microtopography of methionine-enkephalin, dopamine and noradrenaline in the ventral mesencephalon of human control and Parkinsonian brains (1982) (69)
A major locus for several phenotypes of myoclonus–dystonia on chromosome 7q (2001) (69)
EFFICACY AND TOLERABILITY OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER TYPE (1998) (69)
Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer's disease (1989) (69)
Distribution of Catecholamines in the Ventral Mesencephalon of Human Brain, with Special Reference to Parkinson's Disease (1981) (69)
Neuroprotection for Parkinson's disease: Prospects and promises (2003) (69)
High and low affinity [3H]imipramine binding sites in control and parkinsonian brains. (1985) (68)
POST MORTEM STABILITY AND STORAGE IN THE COLD OF BRAIN ENZYMES (1979) (68)
Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system (1994) (68)
Perspectives on recent advances in the understanding and treatment of Parkinson’s disease (2009) (67)
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease (1996) (67)
Bromocriptine and domperidone in the treatment of Parkinson disease (1981) (67)
FADD: A link between TNF family receptors and caspases in Parkinson’s disease (2002) (67)
Autosomal‐dominant cerebellar ataxia with retinal degeneration (ADCA type II) is genetically different from ADCA type I (1994) (67)
The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? (1990) (67)
Movement disorders and inborn errors of metabolism in adults: A diagnostic approach (2008) (66)
Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum (1989) (66)
Micro topography of Tyrosine Hydroxylase, Glutamic Acid Decarboxylase, and Choline Acetyltransferase in the Substantia Nigra and Ventral Tegmental Area of Control and Parkinsonian Brains (1981) (66)
Errors of memory-guided saccades in humans with lesions of the frontal eye field and the dorsolateral prefrontal cortex. (1999) (65)
Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment (2005) (65)
The gene for autosomal dominant cerebellar ataxia type II is located in a 5-cM region in 3p12-p13: genetic and physical mapping of the SCA7 locus. (1996) (65)
Immunocytochemical Quantification of Tyrosine Hydroxylase at a Cellular Level in the Mesencephalon of Control Subjects and Patients with Parkinson's and Alzheimer's Disease (1993) (65)
Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD67 mRNA (1995) (64)
Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset (1998) (64)
Distribution of manganese-dependent superoxide dismutase in the human brain (1994) (63)
Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6‐hydroxydopamine lesion of the nigrostriatal pathway (1973) (62)
Does ageing aggravate parkinsonian disability? (1991) (61)
Feedback control of dopamine synthesis in dopaminergic terminals of the rat striatum. (1972) (61)
Apolipoprotein E ϵ4 Allele and Familial Aggregation of Alzheimer Disease (1998) (61)
Back problems in Parkinson's disease: an underestimated problem. (2006) (61)
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study (1997) (60)
Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible? (2000) (60)
Functional Activity of Zona Incerta Neurons Is Altered after Nigrostriatal Denervation in Hemiparkinsonian Rats (2000) (60)
Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. (1989) (59)
Planning and Script Analysis following Prefrontal Lobe Lesions a (1995) (59)
Acute deep-brain stimulation of the internal and external globus pallidus in primary dystonia: functional mapping of the pallidum. (2007) (59)
Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy (1995) (59)
Dementia in Parkinson's disease: Biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins (1993) (58)
Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. (1987) (58)
Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. (2003) (58)
Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease (1989) (57)
Recombination hot spot in a 3.2-kb region of the Charcot-Marie-Tooth type 1A repeat sequences: new tools for molecular diagnosis of hereditary neuropathy with liability to pressure palsies and of Charcot-Marie-Tooth type 1A. French CMT Collaborative Research Group. (1996) (57)
DYT1 mutation in French families with idiopathic torsion dystonia. (1999) (57)
“Pure” striatonigral degeneration and Parkinson's disease: A comparative clinical study (1995) (57)
Quality of life predicts outcome of deep brain stimulation in early Parkinson disease (2019) (56)
Distribution of 125I‐Ferrotransferrin Binding Sites in the Mesencephalon of Control Subjects and Patients with Parkinson's Disease (1993) (55)
Acute severe depression induced by intraoperative stimulation of the substantia nigra: a case report. (2008) (55)
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. (2007) (55)
Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. (1983) (55)
PROGRESSIVE SUPRANUCLEAR PALSY: LOSS OF STRIATAL DOPAMINE RECEPTORS DEMONSTRATED IN VIVO BY POSITRON TOMOGRAPHY (1985) (54)
Adenosine Prevents the Death of Mesencephalic Dopaminergic Neurons by a Mechanism that Involves Astrocytes (1999) (54)
Characterization and visualization of neurotensin binding to receptor sites in human brain. (1984) (54)
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism (2003) (54)
GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys (1993) (53)
Rescue of Mesencephalic Dopamine Neurons by Anticancer Drug Cytosine Arabinoside (1997) (53)
Urinary disturbances in striatonigral degeneration and parkinson's disease: Clinical and urodynamic aspects (1997) (53)
Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. (1981) (53)
Dissociation of neuropeptide Y and somatostatin in Parkinson's disease (1985) (53)
Frequency of the DYT1 mutation in primary torsion dystonia without family history. (2000) (52)
Decrease in [3H]cocaine binding to the dopamine transporter in Parkinson's disease. (1983) (52)
Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. (1999) (52)
Relationship of aging to Parkinson's disease. (1987) (52)
Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado‐Joseph disease (1998) (52)
Somatotopical organization of striatal activation during finger and toe movement: A 3‐T functional magnetic resonance imaging study (1998) (52)
Dopamine D‐1 Receptor and Cyclic AMP‐Dependent Phosphorylation in Parkinson's Disease (1987) (51)
Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy (1991) (51)
Sequences of memory‐guided saccades in Parkinson's disease (1994) (50)
Toxic Effects of Iron for Cultured Mesencephalic Dopaminergic Neurons Derived from Rat Embryonic Brains (1992) (50)
Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy (1994) (49)
Phenotypic variability in autosomal dominant cerebellar ataxia type I is unrelated to genetic heterogeneity. (1993) (49)
Clinical and genetic analysis of a Tunisian family with autosomal dominant cerebellar ataxia type 1linked to the SCA2 locus (1994) (49)
Do parkinsonian symptoms and levodopa‐induced dyskinesias start in the foot? (1994) (49)
Somatostatin messenger rna-containing neurons in Alzheimer's disease: An in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex (1994) (48)
Regional Distribution of Neurotransmitter Synthesizing Enzymes in the Basal Ganglia of Human Brain (1980) (48)
Parkinson's disease, subthalamic stimulation, and selection of candidates: A pathological study (2003) (48)
Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. (1991) (47)
Quantitative Autoradiography of Tyrosine Hydroxylase Immunoreactivity in the Rat Brain (1991) (47)
Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). (1998) (47)
BRAIN HISTIDINE DECARBOXYLASE ACTIVITY IN PARKINSON'S DISEASE (1983) (47)
Spatio-Temporal Working Memory and Frontal Lesions in Man * * A subset of this data was presented at the XXVI International Congress of Psychology, Montreal, August 1996. (1998) (47)
Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (1999) (47)
[The L-dopa test in Parkinson's disease]. (1985) (47)
Differential distribution of the normal and mutated forms of huntingtin in the human brain (1997) (47)
A large pedigree with early-onset Alzheimer's disease (1995) (47)
Linkage disequilibrium at the Machado-Joseph disease/spinal cerebellar ataxia 3 locus: evidence for a common founder effect in French and Portuguese-Brazilian families as well as a second ancestral Portuguese-Azorean mutation. (1995) (46)
Cortical cholinergic projections from the basal forebrain of the rat, with special reference to the prefrontal cortex innervation (1984) (46)
Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain (1992) (46)
Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. (1998) (46)
Distribution of semaphorin IV in adult human brain (1999) (46)
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa‐induced motor alterations in Parkinsonian rats (2001) (46)
The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease (1997) (45)
Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography. (1999) (45)
Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. (1996) (45)
Ipsilateral and contralateral subthalamic activity after unilateral dopaminergic lesion (2000) (45)
Effects of pulse width variations in pallidal stimulation for primary generalized dystonia (2007) (45)
Control of vertical components of gait during initiation of walking in normal adults and patients with progressive supranuclear palsy. (2007) (44)
An Effect of Dopamine Depletion on Decision-making: The Temporal Coupling of Deliberation and Execution (2005) (44)
Nerve cell death in degenerative diseases of the central nervous system: clinical aspects. (1987) (44)
Enkephalinergic Markers in Substantia Nigra and Caudate Nucleus from Parkinsonian Subjects (1984) (43)
Tyrosine kinase B messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study (1998) (43)
Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism (2003) (43)
Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy (1998) (43)
Parkinson's disease is a neuropsychiatric disorder. (2003) (43)
Dynorphin levels in parkinsonian patients: Leu5-enkephalin production from either proenkephalin A or prodynorphin in human brain (1985) (42)
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations (2007) (42)
Saccade disturbances after bilateral lentiform nucleus lesions in humans. (1996) (42)
Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease (1992) (42)
Deep brain stimulation in Parkinson's disease: Opposite effects of stimulation in the pallidum (1998) (41)
Hereditary neuralgic amyotrophy and hereditary neuropathy with liability to pressure palsies (1994) (41)
Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation (2019) (41)
Experimental Approach to Prefrontal Functions in Humans (1995) (41)
Levodopa: why the controversy? (2002) (41)
Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. (2003) (41)
Concentration Gradients of Free and Total γ‐Aminobutyric Acid and Homocarnosine in Human CSF: Comparison of Suboccipital and Lumbar Sampling (1982) (41)
Chemical or electrolytic lesion of the substantia nigra: early effects on neostriatal dopamine metabolism. (1974) (40)
Adverse reactions to levodopa: drug toxicity or progression of disease? (1998) (40)
Levels of MET-enkephalin, LEU-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment (1988) (40)
Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer's disease. (1997) (40)
Psychosocial adjustment after deep brain stimulation in Parkinson's disease (2008) (40)
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. (1999) (40)
Mechanisms of apoptosis in PC12 cells irreversibly differentiated with nerve growth factor and cyclic AMP (1999) (40)
Deficit in Evaluating Pre-Determinated Sequences of Script Events in Patients with Parkinson's Disease (1998) (39)
Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine (1995) (39)
A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations (2009) (39)
Camptocormia and Parkinson’s disease: MR imaging (2008) (39)
14‐3‐3 Protein cerebrospinal fluid detection in human growth hormone–treated Creutzfeldt‐Jakob disease patients (2001) (39)
[Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation]. (1985) (39)
Unilateral Thalamic Deep Brain Stimulation for Disabling Kinetic Tremor in Multiple Sclerosis (2012) (39)
High-level gait and balance disorders in the elderly: a midbrain disease? (2013) (39)
Duplication within chromosome 17p11.2 in 12 families of French ancestry with Charcot-Marie-Tooth disease type 1a. The French CMT Research Group. (1992) (38)
Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects (1987) (38)
Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes (1990) (38)
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? (2000) (38)
Multiple origins of the spinocerebellar ataxia 7 (SCA7) mutation revealed by linkage disequilibrium studies with closely flanking markers, including an intragenic polymorphism (G3145TG/A3145TG) (1999) (38)
Ropinirole without levodopa in Parkinson's disease (1990) (38)
Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. (1992) (37)
The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures (1992) (37)
De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. (1998) (37)
Parkinson disease, brain volumes, and subthalamic nucleus stimulation (2005) (36)
Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon (1993) (36)
Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys (1995) (36)
Effect of low and high frequency thalamic stimulation on sleep in patients with Parkinson's disease and essential tremor (2000) (36)
Cellular localization of adrenergic receptors in rat and human brain (1986) (36)
Clinical and pathological features in hydrocarbon‐induced Parkinsonism (1996) (35)
Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME) (2002) (35)
Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. (2007) (35)
Diagnosis of “sporadic” Huntington's disease (1995) (34)
Tolcapone, bromocriptine, and Parkinson's disease (1997) (34)
Bromocriptine in Parkinson's disease: a study of cardiovascular effects. (1981) (34)
The parkin gene and its phenotype (2001) (34)
Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography (1994) (34)
Alzheimer's disease: Is the decrease of the cholinergic innervation of the hippocampus related to intrinsic hippocampal pathology? (1992) (34)
Role of pontine nuclei damage in smooth pursuit impairment of progressive supranuclear palsy (1994) (33)
[Aging, disease and nerve cell death]. (1995) (33)
How Patients with Parkinson's Disease Retrieve and Manage Cognitive Event Knowledge (2000) (33)
Choline acetyltransferase mRNA expression in the striatal neurons of patients with Alzheimer's disease (1997) (33)
Glycine Receptors in the Human Substantia Nigra as Defined by [3H]Strychnine Binding (1982) (32)
METHIONINE-ENKEPHALIN DEFICIENCY IN BRAINS OF PATIENTS WITH PARKINSON'S DISEASE (1981) (32)
Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. (2003) (32)
[3H]imipramine binding in subcellular fractions of rat cerebral cortex after chemical lesion of serotonergic neurons. (1983) (32)
Linkage disequilibrium between the spinocerebellar ataxia 3/Machado-Joseph disease mutation and two intragenic polymorphisms, one of which, X359Y, affects the stop codon. (1997) (32)
Atypical Gilles de la Tourette Syndrome With β-Mannosidase Deficiency (2006) (32)
Pathophysiology of L-dopa-induced abnormal involuntary movements. (1985) (32)
Dopaminergic receptor sites in human brain (1985) (32)
Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? (1995) (32)
Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus (2007) (32)
Pro-opiomelanocortin peptides in the human hypothalamus: Comparative study between normal subjects and parkinson patients (1985) (32)
Localization of copper-zinc superoxide dismutase mRNA in human hippocampus by in situ hybridization (1989) (31)
In-vivo SPECT imaging of D2 receptor with iodine-iodolisuride: results in supranuclear palsy. (1992) (31)
The gene for spinal cerebellar ataxia 3 (SCA3) is located in a region of approximately 3 cM on chromosome 14q24.3-q32.2. (1995) (31)
Adrenergic receptors in frontal cortex in human brain. (1985) (31)
Are parkin patients particularly suited for deep‐brain stimulation? (2008) (31)
A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. (2009) (31)
Lack of Change in Basal Ganglia Neuropeptide Content Following Subacute 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Treatment of the Common Marmoset (1986) (31)
[Neuronal death caused by apoptosis in Parkinson disease]. (1997) (31)
A de novo case of hereditary neuropathy with liability to pressure palsies (HNPP) of maternal origin: a new mechanism for deletion in 17p11.2? (1996) (30)
Neurochemical Investigations into the Human Area Postrema (1986) (30)
Irregular jerky tremor, myoclonus, and thalamus: A study using low‐frequency stimulation (2000) (30)
Influence of sensory inputs and motor demands on the control of the centre of mass velocity during gait initiation in humans (2010) (30)
The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. (1998) (30)
Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man (1990) (30)
Long-term effects of unilateral 6-hydroxydopamine destruction of the dopaminergic nigrostriatal pathway on the urinary excretion of catecholamines (dopamine, norepinephrine, epinephrine) and their metabolites in the rat (1978) (29)
In vivo estimation of tyrosine hydroxylation in the dopaminergic terminals of the rat neostriatum (1974) (29)
Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem. (1993) (29)
Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. (1998) (29)
Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects. (1982) (28)
Expression of tachykinin NK2 receptor mRNA in human brain (2001) (28)
Cholinergic-dependent cognitive deficits in Parkinsonʼs disease (1988) (28)
Retrospective Cross-Evaluation of an Histological and Deformable 3D Atlas of the Basal Ganglia on Series of Parkinsonian Patients Treated by Deep Brain Stimulation (2005) (28)
Age-related changes of neuronal counts in the human pedunculopontine nucleus (2000) (28)
Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives. (1995) (28)
The relationship between differentiation and survival in PC12 cells treated with cyclic adenosine monophosphate in the presence of epidermal growth factor or nerve growth factor (2001) (28)
Microtopography of d1 dopaminergic binding sites in the human substantia nigra: An autoradiographic study (1990) (27)
Neuropeptides and Parkinson's disease. (1986) (27)
Dopamine and methionine-enkephalin in human brain (1982) (27)
Cholinergic Systems in Alzheimer’s Disease, Parkinson’s Disease and Progressive Supranuclear Palsy (1990) (27)
Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study (1998) (27)
DA Uptake Sites, D1, and D2 Receptors, D2 and Preproenkephalin mRNAs and Fos Immunoreactivity in Rat Striatal Subregions after Partial Dopaminergic Degeneration (1996) (26)
l‐Histidine Decarboxylase in the Human Brain: Properties and Localization (1980) (26)
trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study. (1998) (26)
Striatal expression of substance P and methionin-enkephalin genes in patients with Parkinson's disease (1995) (25)
Nuclear translocation of NFk B is increased in dopaminergic neurons of patients with Parkinson disease (1997) (25)
High frequency of mutations in codon 98 of the peripheral myelin protein P0 gene in 20 French CMT1 patients. (1996) (25)
Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. (1996) (24)
No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. (1996) (24)
Brain muscarinic cholinergic receptors in Huntington's disease (1992) (24)
Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. (1995) (24)
Dementia in Parkinson’s Disease (1988) (24)
Cholinergic neuronal loss in the globus pallidus of Alzheimer disease patients (1991) (23)
[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy (1991) (23)
Use of haplotype information to test involvement of the LRP gene in Alzheimer's disease in the French population (2001) (23)
[In vivo study of central serotoninergic receptors in man using positron tomography]. (1985) (23)
Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum (1993) (23)
Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study (2010) (23)
Tyrosine hydroxylase gene expression in human ventral mesencephalon: Detection of tyrosine hydroxylase messenger RNA in neurites (1990) (23)
Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study (1997) (22)
Genetic heterogeneity of autosomal dominant cerebellar ataxia type 1 (1993) (22)
Contrasting Changes in Cortical Activation Induced by Acute High-Frequency Stimulation within the Globus Pallidus in Parkinson's Disease (2009) (22)
Segmental progression of early untreated Parkinson’s disease: a novel approach to clinical rating (2009) (22)
Parkinson's disease: neurosurgery at an earlier stage? (2002) (22)
Decrease of serotonin‐S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy (1988) (22)
Parkinson's Disease and Dementia (1986) (21)
Dual-release formulation, a novel principle in l-dopa treatment of Parkinson’s disease (2001) (21)
Singing in the brain: a new form of complex partial seizure? (1989) (21)
Characterisation of the unstable expanded CAG repeat in the MJD1 gene in four Brazilian families of Portuguese descent with Machado-Joseph disease (1995) (21)
Memory guided saccade deficit after caudate nucleus lesion (1999) (21)
Survival factors promote BDNF protein expression in mesencephalic dopaminergic neurons. (1999) (21)
Biochemical mapping of cholecystokinin-, substance P-, [met]enkephalin-, [leu]enkephalin- and dynorphin a (1–8)-like immunoreactivities in the human cerebral cortex (1988) (21)
Concurrent excitatory and inhibitory effects of high frequency stimulation: an oculomotor study (2002) (20)
The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. (2001) (20)
Facilitory paratonia and frontal lobe functioning. (1999) (20)
CD 23 Is Expressed in Parkinson ’ s Disease and Induces , In Vitro , Production of Nitric Oxide and Tumor Necrosis Factor-a in Glial Cells (1999) (20)
A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine (1995) (20)
Orthostatic tremor in monozygotic twins (2006) (20)
Increased wave P 300 latency in progressive supranuclear palsy. (1989) (19)
["Beginning and end of dose" dyskinesias caused by L-DOPA]. (1977) (19)
[From posture to initiation of movement]. (1990) (19)
Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease (2000) (19)
Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy (1988) (19)
Dopamine receptors and cholinergic neurons in the rat neostriatum. (1975) (19)
Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease (1989) (18)
Prenatal diagnosis of Friedreich ataxia (1990) (18)
Comparison of [3H] phencyclidine ([3H] PCP) and [3H] N-[1-(2-thienyl) cyclohexyl] piperidine ([3H] TCP) binding properties to rat and human brain membranes. (1989) (18)
Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease (1996) (18)
Saccades and antisaccades in parkinsonian syndromes. (1999) (18)
MOTONEURON DISEASE AS MANIFESTATION OF LUPIN SEED TOXICITY (1988) (18)
Adult‐onset chorea and mitochondrial cytopathy (2005) (18)
Dihydropteridine reductase deficiency: Levodopa’s long-term effectiveness without dyskinesia (2006) (18)
Somatostatin receptors in brain and pituitary. (1989) (18)
Brain neuropeptides in progressive supranuclear palsy (1987) (17)
D2 dopamine receptor gene in myoclonic dystonia and essential myoclonus (2000) (17)
Overactivity of cervical premotor neurons in Parkinson’s disease (1998) (17)
Molecular Mechanisms of Neuronal Cell Death: Implications for Nuclear Factors Responding to cAMP and Phorbol Esters (2002) (17)
Does unilateral basal ganglia activity functionally influence the contralateral side? What we can learn from STN stimulation in patients with Parkinson's disease. (2012) (17)
Evidence for the Existence of a Dopaminergic Innervation of the Rat and Human Hippocampal Formation (1982) (17)
The gene for Machado–Joseph disease maps to the same 3-cM interval as the spinal cerebellar ataxia 3 gene on chromosome 14q (1994) (17)
Induction of calbindin‐D 28K gene and protein expression by physiological stimuli but not in calcium‐mediated degeneration in rat PC12 pheochromocytoma cells (1994) (17)
No effect of the α1-antichymotrypsin A allele in Alzheimer’s disease (1997) (17)
An immunocytochemical study of a G‐proteingated inward rectifier K+ channel (GIRK2) in the weaver mouse mesencephalon (1997) (17)
The gene for spinal cerebellar ataxia 3 (SCA3) is located in a region of ∼3 cM on chromosome 14q24.3-q32.2 (1995) (17)
Clinical and genetic analysis of a Tunisian family with autosomal dominant cerebellar ataxia type 1 linked to the SCA2 locus. (1994) (16)
Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease (2004) (16)
Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea (1987) (16)
Pitfalls in membrane binding sites studies in post-mortem human brain. (1987) (16)
Pharmacologic Studies in Man with PET: An Investigation Using 11C-Labeled Ketanserin, a 5 HT2 Receptor Antagonist (1985) (16)
Cerebrospinal fluid homocarnosine in Huntington's disease. (1980) (16)
[Parkinson disease: mechanisms of cell death]. (2002) (16)
Autoradiographic Visualization and Quantification of Dopamine Receptors and Uptake Sites in the Rat and Human CNS (1986) (16)
Periodic leg movements and REM sleep without atonia in Parkinson's disease with camptocormia (2009) (16)
The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom (2011) (15)
[3H]spiperone binding in the nigrostriatal system in human brain. (1984) (15)
α2‐Macroglobulin gene and Alzheimer's disease: Confirmation of association by haplotypes analyses (2000) (15)
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects. (1985) (15)
Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects. (1987) (15)
Effect of Chronic Treatment with Riluzole on the Nigrostriatal Dopaminergic System in Weaver Mutant Mice (2002) (15)
monoclonal antibodies raised against Lewy bodies in brains from subjects with Parkinson's disease (1985) (15)
Autosomal dominant cerebellar ataxia type I linked to chromosome 12q (SCA2: spinocerebellar ataxia type 2). (1995) (15)
Death of septal cholinergic neurons produced by chronic exposure to glutamate is prevented by the noncompetitive NMDA receptor/channel antagonist, MK‐801: Role of nerve growth factor and nitric oxide (1995) (15)
Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects (1988) (15)
Disappearance of parkinsonian signs after spontaneous vascular 'thalamotomy'. (1986) (15)
A Controlled Study of Oral Vigabatrin (ɣ-Vinyl GABA) in Patients with Cerebellar Ataxia (1986) (15)
Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects. (1999) (14)
Dopamine receptor stimulating agonists in the treatment of Parkinson's disease. (1979) (14)
Thyrotropin releasing hormone content is unchanged in brains of patients with Parkinson disease (1983) (14)
Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome (2019) (14)
At the Origin of the History of Glia (2018) (14)
Is dopaminergic cell death accompanied by concomitant nerve plasticity? (1996) (14)
Microsatellite mapping of the deletion in patients with hereditary neuropathy with liability to pressure palsies (HNPP): new molecular tools for the study of the region 17p12 --> p11 and for diagnosis. (1996) (14)
Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease (2001) (14)
Effect of Gamma-Vinyl GABA in Friedreich’s Ataxia (1982) (13)
Duplication within chromosome 17 p 11 . 2 in 12 families of French ancestry with Charcot-Marie-Tooth disease type la (13)
Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease (1994) (13)
Expression of Trk Isoforms in Brain Regions and in the Striatum of Patients with Alzheimer's Disease (2000) (13)
Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease (1994) (13)
LRP10 in α-synucleinopathies (2018) (13)
[Parkinson syndrome, frontal tumor and L-dopa]. (1984) (13)
In situ hybridization of GAD mRNA in monkey and human brain: quantification at both regional and cellular levels (1993) (13)
Linkage analyses between dominant X-linked Charcot-Marie-Tooth disease, and 15 Xq11–Xq21 microsatellites in a new large family: Three new markers are closely linked to the gene (1994) (13)
Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA (2002) (13)
Dopamine deficiency in Parkinson's disease (1984) (13)
Atypical Gilles de la Tourette Syndrome with beta-mannosidase deficiency. (2006) (12)
Striatal dopaminergic denervation in Pallidopyramidal disease demonstrated by positron emission tomography (1995) (12)
Gangliosides and parkinsonism (1993) (12)
Does frontal cortex hypometabolism in progressive supranuclear palsy result from subcortical dysfunction? (1995) (12)
High affinity neurotrophin receptors in cholinergic neurons in the human brain. (1994) (11)
Multiple sclerosis tremor and the Stewart‐Holmes manoeuvre (2003) (11)
Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease. (1993) (11)
Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy (1988) (11)
Huntington's disease in French families: CAG repeat expansion and linkage disequilibrium analysis. (1993) (11)
[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA]. (1977) (11)
Amyloid-β in Alzheimer's Disease: A Study of Citation Practices of the Amyloid Cascade Hypothesis Between 1992 and 2019. (2020) (11)
Positron Emission Tomography Study of Brain Benzodiazepine Receptors in Friedreich's Ataxia (1990) (11)
Erratum: Neurogeneration and prospects for neuroprotection and rescue in Parkinson's disease (Annals of Neurology (53:S4)) (2003) (11)
Dopamine denervation, age of onset, and Parkinson's disease (1995) (11)
Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area. (1996) (10)
Segregation analysis of Alzheimer pedigrees: rare Mendelian dominant mutation(s) explain a minority of early-onset cases. French Alzheimer Collaborative Group. (1996) (10)
Parkinsonian Disorders in Clinical Practice (2009) (10)
Hippocampal and Parahippocampal Somatostatin 28 and Neuropeptide Y Containing Neurons in Alzheimer's Disease (Part 1 of 2) (1992) (10)
La maladie de Charcot-Marie-Tooth (2009) (10)
SCA2 is not a major locus for ADCA type I in French families. (1995) (10)
Familial Parkinson's disease and polymorphism at the CYP2D6 locus. (1994) (9)
Low affinity nerve growth factor receptor, adrenal transplant and Parkinson's disease (1993) (9)
Is DRPLA also linked to 14q? (1994) (9)
Brain Regional Pharmacokinetics of 11C-Labeled Diphenylhydantoin and Pimozide in Man (1983) (9)
[Study of cortical atrophy with magnetic resonance imaging in corticobasal degeneration]. (1998) (9)
Regional and cellular presenilin 2 (STM2) gene expression in the human brain. (1996) (9)
Exclusion of the Nurr1 gene in autosomal recessive Parkinson’s disease (2002) (8)
The G2019SLRRK2 Mutation in Autosomal Dominant European and North African Parkinson’s Disease is Frequent and its Penetrance is Age-Dependant (2005) (8)
Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies): Genetic analysis of three unrelated SCA2 families (1996) (8)
Genetic heterogeneity of autosomal dominant cerebellar ataxia type I: evidence for the existence of a third locus. (1993) (8)
Dyskinesias assessment in Phase II studies. (1999) (8)
Is the early-onset torsion dystonia (EOTD) linked to TOR1A gene as frequent as expected in France? (2008) (7)
Subthalamic Stimulation in Parkinson Disease (2016) (7)
Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial. (2019) (7)
Unexpected aggravation of Parkinson’s disease by a mesencephalic multiple sclerosis lesion (2004) (7)
BIOCHEMICAL AND MORPHOLOGICAL CHANGES AFTER MECHANICAL OR CHEMICAL DEGENERATION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PATHWAY (1974) (7)
Tyrosine hydroxylase-like immunoreactivity in senile plaques is not related to the density of tyrosine hydroxylase-positive fibers in patients with Alzheimer's disease (1990) (7)
Characterization of two antigens in parkinsonian Lewy bodies (1988) (7)
Severity and Specificity of Cognitive Impairment in Alzheimer's, Huntington's, and Parkinson's Diseases and Progressive Supranuclear Palsy (1991) (6)
Continuous high frequency stimulation of deep brain structures in brain pathology (1999) (6)
[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)]. (1981) (6)
[Neuropharmacologic approach in Huntington's chorea]. (1975) (6)
Somatostatin alterations and brain diseases. (1985) (6)
Maladie de Parkinson: mécanismes de la mort cellulaire. (2002) (6)
[125I]EGF Binding in Basal Ganglia of Patients with Parkinson's Disease and Progressive Supranuclear Palsy and in MPTP-Treated Monkeys (1998) (6)
What Does Apoptosis Have To Do With Parkinson ’ s Disease ? (6)
Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Commentary (1998) (6)
Brain somatostatin concentrations do not decrease in progressive supranuclear palsy. (1987) (6)
Cognitive deficits in non-Alzheimer's degenerative diseases. (1996) (6)
WHAT CAUSES PARKINSON'S DISEASE? (1984) (6)
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. (2003) (5)
Aging, disease and death of nerve cells. (1996) (5)
The IMAO-B MDL 72.974 A in Parkinson's disease. (1992) (5)
Gender equality in Machado–Joseph disease (1995) (5)
[Acetylcholine receptors (author's transl)]. (1979) (5)
[Parkinson's disease: cell death mechanisms] (2002) (5)
Ultrastructural relations between nigrostriatal dopaminergic neurons and cholinergic nerve endings in the human brain. (1993) (5)
Doescognitive impairment inParkinson's disease result fromnon-dopaminergic lesions? (1989) (5)
Exclusion of the candidate locus FSP1 in six families with late-onset autosomal dominant spastic paraplegia (1995) (5)
Will neurological practice be different during the 21st century. (2000) (5)
Dementia in Patients with Parkinson’s Disease: Review of Biochemical Data (1985) (5)
Neurostimulation for Parkinson's disease with early motor complications. (2013) (5)
Dystonies et tremblements d'utilisation instrumentale répétitive. (2008) (5)
Cortical vasoactive intestinal peptide in relation to dementia in Parkinson's disease. (1985) (5)
[Iatrogenic Creutzfedt-Jacob disease. What precautions are to be taken for the prevention of neurosurgical contamination?]. (1995) (4)
Autoradiographic study of [125Iepidermal growth factor-binding sites in the mesencephalon of control and parkinsonian brains post-mortem (1993) (4)
No mutation in codon 713 of the amyloid precursor gene in schizophrenic patients. (1993) (4)
Blockade of cholecystokinin-A receptors has no effect on dyskinesias in Parkinson's disease (2001) (4)
[Does the ataxo-choreic form of DRPLA exist in Europe? Search of mutation in 120 families]. (1995) (4)
Cortical dysfunction and schizophrenic deficit. Preliminary findings with the delayed reaction paradigm (1992) (4)
Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group. (1997) (4)
Acetylcholinesterase and butyrylcholinesterase in cerebrospinal fluid from patients with dystonia. (1988) (4)
Adrenal transplant, dopaminergic neurons, and Parkinson' disease (1993) (4)
Levodopa. Is toxicity a myth? 1998. (2001) (4)
What is Parkinson's Disease? From Pathophysiology to Symptoms (2009) (4)
[How to examine a patient with Parkinson disease]. (2000) (4)
Neuronal plasticity and Parkinson disease. (1995) (4)
Glycine receptors in the human brain: characterization of 3H-strychnine binding and status in pathological conditions. (1983) (4)
Levodopa (1998) (4)
MK-801 does not prevent dopaminergic cell death induced by MPP+ in rat mesencephalic cultures (1992) (3)
Enkephalin dipeptidyl carboxypeptidase ("enkephalinase"): assay, properties, and distribution in human brain and exploration of the active site. (1982) (3)
Early effects of monoamine oxidase inhibitors on dopamine metabolism and monoamine oxidase activity in the neostriatum of the rat (2005) (3)
Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS): Design and progress report of a clinical trial of the efficacy and safety of riluzole in Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) (2002) (3)
Deterioration of dopaminergic pathways and alterations in cognition and motor functions (1992) (3)
Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
[Influence of choline on amnesia in Alzheimer's disease (author's transl)]. (1979) (3)
Simultaneous measurement of β-endorphin- and γ-lipotropin-like peptides in the human hypothalamus (1981) (3)
Rapport 19-04. L’enfant, l’adolescent, la famille et les écrans : appel à une vigilance raisonnée sur les technologies numériques (2019) (3)
[Phenotype of familial forms of early-onset Alzheimer's disease linked to chromosome 14. Clinical and neuropsychological characteristics of a large group]. (1995) (3)
The role of the pallidum in Parkinson's disease gait. Lessons from pallidal stimulation. (2001) (3)
Current Trends in the Treatment of Parkinson's Disease (1992) (3)
STRIATAL GLUTAMATE DECARBOXYLASE VALUES, INDICATIVE OF HOSPITAL WHERE PATIENT DIED (1984) (3)
Génétique de la maladie de Parkinson (1999) (3)
Autosomal dominant paroxysmal kinesigenic choreoathetosis: a clinical and genetic study of two families (1998) (3)
[Selective action of neuroleptics on the cholinergic neurons of the neostriatum in the rat: antagonism to apomorphine]. (1974) (2)
Parkinson's disease or Parkinson's diseases? (1999) (2)
[Genetics of Alzheimer's disease]. (1996) (2)
[Parkinson's disease: some physiopathologic aspects and clinical practice]. (1989) (2)
REGULATION OF DA SYNTHESIS IN THE NIGRO NEOSTRIATAL SYSTEM (1973) (2)
Étude de l'atrophie corticale par imagerie par résonance magnétique dans la dégénérescence cortico-basale (1998) (2)
[Genetics of Parkinson disease]. (1999) (2)
Exploring the Myths about Parkinson’s Disease (2009) (2)
The role of the parietal cortex in the representation of hand movements: a fMRI study (1998) (2)
L’autre moitié du cerveau les cellules gliales (2019) (2)
Effect of a methionine-enkephalin analog in Huntington's disease. (1983) (2)
Does Unilateral Basal Ganglia Activity Functionally Influence the Contralateral Side? What 1 We Can Learn from Stn Stimulation in Parkinson's Disease Patients. 2 (2012) (2)
Delineation of the basal ganglia in MR images of patients by automatic registration of a multimodal atlas based on histological and MR data (2003) (2)
Low‐dose CU 32‐085 (Mesulergine) in previously untreated Parkinson? disease (1984) (2)
Pergolide in the treatment of Parkinson's disease (1984) (2)
Subconscious man: The basal ganglia as a target for intervention in emotional disorders (2013) (2)
Autosomal dominant cerebellar ataxia type I in Morocco: presence of the SCA1 and SCA3/MJD mutations (1996) (2)
[Mechanism of cell death in neurodegenerative disorders: apropos of Parkinson disease]. (1993) (2)
Les facteurs génétiques dans l'étiologie de la maladie d'Alzheimer. (1996) (2)
Ataxie cérébelleuse autosomique dominante avec dystrophie maculaire progressive : un modèle d'étude des maladies dues à une expansion de polyglutamine. (1998) (2)
Mutations in the neuroserpin gene are rare in familial dementia (2000) (1)
Confusion, dementia andanticholinergics inParkinson's disease (1982) (1)
Toxic effects of iron for dopaminergic neurons derived from rat mesencephalon (1992) (1)
Eye Movements in Pmhnsonian Syndromes (1994) (1)
784 Genetic studies of Alzheimer's disease in 434 French families (1996) (1)
No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. (1997) (1)
Contents Vol. 53, 2005 (2005) (1)
Neuroanatomy of Dopaminergic System in the Human Brain (1991) (1)
Primary orthostatic tremor and unsteadiness (2004) (1)
Continuous Stimulation of the Globus Pallidus and Subthalamic Nucleus in Parkinson’s Disease (2002) (1)
[Clinical diagnostic criteria for multiple system atrophy]. (1998) (1)
DISTRIBUTION IN THE BRAIN AND SPINAL CORD (RAT AND HUMAN) OF ENKEPHALIN TARGETS (μ, δ OPIOID RECEPTORS AND ENKEPHALINASE) IN VARIOUS PHYSIOPATHOLOGICAL CONDITIONS (1987) (1)
No e V ect of the á 1-antichymotrypsin A allele in Alzheimer ’ s disease (1998) (1)
Commentary: Dealing with the Aftermath. (2016) (1)
[Creutzfeldt-Jakob disease after treatment with growth hormone: the point in July, 1998]. (1998) (1)
Cloning of the gene for autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7) reveals a highly unstable CAG repeat expansion (1997) (1)
Progressive Supranuclear Palsy Studied by Pet (1987) (1)
Treatment of Huntington disease with γ ‐acetylenic GABA, an irreversible inhibitor of GABA‐ transaminase (1981) (1)
Biochemical Neuropathology: A New Approach to Parkinson’s Disease (1985) (1)
Smooth pursuit in progressive supranuclear palsy (1995) (1)
USEFULNESS OF RECEPTOR BINDING STUDIES IN HUMAN BRAIN (1984) (1)
The effects of apomorphine on attentional processing in Parkinson's disease. (1999) (1)
Somatotopical organization of striatal activation during hand and toes movements: A 3T fMRI study (1997) (1)
Dopaminergic modulation of cognition in Parkinson's disease: the effects of apomorphine (1998) (1)
[Can subthalamic nucleus stimulation reveal parkinsonian rest tremor?]. (2009) (1)
[Meningo-myelitis with a favorable course after measles vaccination]. (1984) (1)
[Dystonia, tremor and repetitive instrumental use]. (2008) (1)
Gilles de la Tourette's Syndrome Centenary Symposium (1985) (1)
Contents Vol. 3, 1992 (1992) (1)
[Parkinson's diseases: power of search]. (2010) (1)
[The other half of the brain… glial cells]. (2019) (1)
Efficacité des effets moteurs et non moteurs de la stimulation pallidale bilatérale dans la dystonie généralisée primaire : trois ans d’évolution (2007) (1)
Les bases neuronales des troubles psychiques (2005) (1)
Un nouveau regard sur les hérédodégénérescences spino-cérébelleuses (1995) (1)
Génétique de la maladie d'Alzheimer (1996) (1)
Neurosciences et maladies du système nerveux (2005) (1)
P2.110 Stimulation of the subthalamic nucleus and substantia nigra: gait analysis in Parkinson's disease patients (2008) (0)
[The genesis of neurosciences: Between technosciences and innovation diplomacy, from the 1940s to the 1970s]. (2021) (0)
[Address from the president of French Society of Neurologists for 2002]. (2003) (0)
Natural History and Neuroprotection in Parkinson Plus Syndromes Parkinson Plus Scale (2014) (0)
Les maladies de Parkinson : les forces de recherche (2010) (0)
Distribution of [3H]SCH 23390 Binding Sites in the Human Substantia Nigra (1991) (0)
Paul Bejjani In Memoriam. (2021) (0)
Subconsciousness, emotional disorders, and basal ganglia. (2017) (0)
Editorial Board (2011) (0)
Paul Bejjani In Memoriam. (2021) (0)
[Neurochemical methods]. (1976) (0)
Reply (1994) (0)
MALADIE DE CREUTZFELDT-JAKOB APRES TRAITEMENT PAR HORMONE DE CROISSANCE : LE POINT EN JUILLET 1998 (1998) (0)
Neuropsychologie des demences (2004) (0)
Subject Index Vol 3, 1992 (1992) (0)
PAW22 Does cortical atrophy take place after basal ganglia damage in multiple system atrophy and progressive supranuclear palsy? (2010) (0)
AN INTERNATIONAL BIBLIOMETRIC STUDY OVER 25 YEARS INTO THE ROLE OF BETA-AMYLOID IN ALZHEIMER’S DISEASE (2019) (0)
Role of the prefrontal cortex in sequential processing of actions and words (1997) (0)
641 Accuracy of the clinical diagnosis of pick's disease (1996) (0)
[Understanding how the brain functions and dysfunctions]. (2013) (0)
Relation ofanosognosia tofrontal lobe dysfunction inAlzheimer's disease (1994) (0)
Why Does Bilateral Subthalamic Stimulation Induced Cognitive Decline in Patients with Parkinson's Disease? (S52.005) (2012) (0)
[Fixation of lanthanum on lung intra-alveolar lipoproteins]. (1969) (0)
Subject Index Vol. 53, 2005 (2005) (0)
The future of clinical neurosciences (2018) (0)
A personal note—Gerald Stern and Yves Agid: A walk in Piazza del Popolo in Rome, sometime in 1998 (2020) (0)
750 On the genetic contribution of Apolipoprotein E e4 allele in Alzheimer's disease transmission (1996) (0)
Higher Level Gait Disorders in the Elderly Subject: Postural Instability, Cortical and Subcortical Abnormalities (P06.077) (2012) (0)
Activation of the striatum during simple movements: Somatotopy at 1.5 T (1999) (0)
degeneration: comparison with Parkinson's disease and progressive supranuclear palsy (0)
Gabaergic systems in parkinsonian syndromes (1987) (0)
Jacques Glowinski, neurobiologist and head of school. (2021) (0)
Foreword. History of the frontal lobe. (2018) (0)
Localization and Density of Transferrin Binding Sites in the Nigrostriatal System of Control Subjects and Patients with Parkinson’s Disease (1995) (0)
Douleurs rachidiennes au cours de la maladie de Parkinson : un problème sous-estimé (2006) (0)
Semi-structured Interview for the Assessment of Repetitive Behaviours Associated with Tics (2014) (0)
Histology and Histopathology Apoptosis and autophagy in nigral neurons of patients with Parkinson ' s disease (2010) (0)
Détérioration des voies dopaminergiques et altérations des fonctions cognitives et motrices (2004) (0)
1.301 HIGHER LEVEL GAIT DISORDERS IN THE ELDERLY SUBJECT: POSTURAL INSTABILITY, CORTICAL AND SUBCORTICAL ABNORMALITIES (2012) (0)
Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
Positron Emission Tomography in Progressive Supranuclear Palsy (2019) (0)
La recherche clinique (2013) (0)
Editorial Board (2004) (0)
Pet study of brain serotonergic 5 ht 2 receptors in alzheimer type dementia atd (1991) (0)
[The origins of neuroscience: Heritage and foundations, from the 19th century to the 1940s]. (2021) (0)
Bromocriptine inParkinson's disease: astudy ofcardiovascular effects (1981) (0)
Role of the prefrontal cortex in sequential processing of actions and words: A 3T fMRI study (1997) (0)
[Treatment of a hallucinatory state with diurnal hypersomnia using oxolinic acid]. (1978) (0)
Neurodegenerative disorders: Are we wrong? (2022) (0)
Guest Editorial: The Metaphor of Paris. (2020) (0)
Endothelin 1 is not a candidate gene for spinal cerebellar ataxia 1. (1993) (0)
Books Received (2003) (0)
Origin of parkin gene mutations in Europe (2001) (0)
Cortical and subcortical dementia (1984) (0)
CHANGES IN STRIATAL DA METABOLISM INDUCED BY CHOLINERGIC AND ANTICHOLINERGIC NIGRAL STIMULATION IN THE RAT (1973) (0)
Preferential expression of superoxide dismutase gene in the neuromelanin-pigmented neurons of the substantia Nigra: Implications for parkinson's disease (1990) (0)
N ° 122 The Use of Biomedical Techniques for “ Neuroenhancement ” in Healthy Individuals : Ethical Issues Members of the Working Group (2014) (0)
Jacques Glowinski. (2021) (0)
Abnormal movements provoked by l dopa in parkinsons disease correlation with plasma concentrations of dopa and of o methyl dopa (1977) (0)
Behavior, brain and astrocytes. (2017) (0)
Hyperactivité des neurones propriospinaux dans la maladie de Parkinson (1998) (0)
No eVect of the á1-antichymotrypsin A allele in Alzheimer’s disease (1998) (0)
Opioid Peptides and their Relevance for CNS Mechanisms; Role of “Enkephalinase” (Enkephalin-Dipeptidylcarboxypeptidase) as Synaptic Neuropeptidase (1982) (0)
shown with MRI . disease : the role of hippocampal atrophy as Memory disorders in probable Alzheimer ' s and (0)
070 INFLUENCE OF SENSORY INPUTS AND MOTOR DEMANDS ON THE CONTROL OF THE CENTRE OF MASS VELOCITY DURING GAIT INITIATION (2010) (0)
The Concept of Subconsciousness in Alzheimer's and Parkinson's Diseases. (2015) (0)
Parkinson's disease with camptocormia. Commentary (2006) (0)
Contents, Vol. 65, 1994 (1994) (0)
[Information on the consequences of the discovery of the Huntington disease gene]. (1994) (0)
ARE NEW DOPAMINE AGONISTS USEFUL (1984) (0)
Authors' Reply Head Injury Outcome Prediction in the Emergency Department: a Role for Protein S-100b? (0)
[Dopaminergic agonists in Parkinson disease]. (1986) (0)
[Effect of a synthetic analog of enkephalin on the choreic syndrome]. (1982) (0)
Treatment of Parkinson's Disease (2009) (0)
Dopamine agonists for Parkinson's disease (2003) (0)
In-Vivo SPECT Imaging of D2 Receptor with, lodine-lodolisuride: Results in SupranuckÃ¡rPalsy (2006) (0)
Acknowledgment to reviewers (1996) (0)
Editorial Board (2004) (0)
De la posture à l'initiation du mouvement (1990) (0)
[Genetics of Alzheimer's disease]. (1998) (0)
Stimulation pallidale dans la dystonie généralisée primaire: résultats préliminaires (2002) (0)
Chimie et cerveau Ed. 1 (2016) (0)
Compulsions, Parkinson et stimulation (2003) (0)
La primauté des comportements automatiques. Entretien avec Yves Agid (2017) (0)
[Genetics of dominant autosomal forms of Alzheimer disease: 3 genes and one phenotype. Groupe de Recherche Francais sur la Maladie d'Alzheimer]. (1996) (0)
Histoire du cerveau et des neurosciences : repères historiques (XIXe-XXe siècles) (2021) (0)
Faut-il opérer les patients parkinsoniens précocement ? (2004) (0)
Etude de l'hétérogénéité génétique des ataxies cérébelleuses autosomiques dominantes (ADCA) de type I (1994) (0)
Attitude pratique face aux complications de la L-dopathérapie chez les patients parkinsoniens fluctuants (2001) (0)
Restauration du contrôle moteur pendant le sommeil paradoxal au cours de la maladie de Parkinson (2007) (0)
Complications neurologiques infectieuses apres transplantation rénale (1985) (0)
Higher level gait disorders du sujet âgé : instabilité posturale, anomalies corticales et sous-corticales (2011) (0)
Reply: Levodopa in the treatment of Parkinson's disease: Current controversies (2005) (0)
Cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or multiple system atrophy: The NNIPPS project (2003) (0)
Subconsciousness (2021) (0)
La stimulation du noyau subthalamique peut-elle révéler un tremblement de repos parkinsonien ? (2009) (0)
Rôle des ganglions de la base (GB) dans le contrôle postural au cours de l’initiation de la marche (2012) (0)
Allocution du Président sortant en 2002 (2008) (0)
Génétique des formes autosomiques dominantes de la maladie d' Alzheimer: trois gènes et un même phénotype. Groupe de Recherche Francais sur la Maladie d'Alzheimer. (1996) (0)
Effet de la stimulation thalamique sur les fuseaux de sommeil (1998) (0)
CO-24 La camptocormie a-t-elle une origine neurologique centrale ? (2005) (0)
PetPthJ and Parklflson's cusease (1985) (0)
CO-25 - Étude à l’aide d’un atlas histologique 3D de la distribution des plots thérapeutiques de patients parkinsoniens neuro-stimulés présentant une excellente amélioration (2006) (0)
Volumetrie cerebrale en irm 3d dans la maladie de parkinson : correlation avec les troubles de la marche (2007) (0)
Effet de la stimulation cérébrale profonde (SCP) sur la respiration durant la veille et le sommeil (1998) (0)
Chapitre 5 : Vieillissement cérébral ou maladie dégénérative (2020) (0)
Acknowledgement to Reviewers (1994) (0)
Qu’est-ce que vieillir ? Huit questions importantes pour comprendre le vieillissement (2020) (0)
Aux origines des neurosciences (2021) (0)
La stimulation cérébrale profonde (SCP)améliore-t-elle le sommeil des parkinsoniens? (1998) (0)
Troubles obsessionnels compulsifs et neurochirurgie (2005) (0)
Dopamine agonists for Parkinson's disease. Authors' reply (2003) (0)
Neurochirurgie de la maladie de Parkinson : conséquences psychologiques et familiales (2005) (0)
Maladie de Gilles de la Tourette et stimulation cérébrale profonde (2003) (0)
Comprar Parkinson's Disease in Daily Practice | Prasad Godbole | 9781405184052 | Wiley (2009) (0)
Fixation du lanthane sur les lipoprotéines intra-alvéolaires du poumon. (1969) (0)
Thalamic activation during hand movements: A 3T fMRI study (1997) (0)
Characterization of a Signalling Pathway Underlying Neuronal Cell Death After Trophic Support Withdrawal Or TNFα Treatment (1997) (0)
Putative role of tumor necrosis factor in the loss of dopaminergic neurons in Parkinson's disease (1992) (0)
Short report Confusion , dementia and anticholinergics in Parkinson ' s disease (0)
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD (1998) (0)
Reply (2000) (0)
Cortico-subcortical reorganization of the motor system in patients with symptomatic unilateral dystonia (2000) (0)
Subject Index Vol. 65, 1994 (1994) (0)
Maladie de Parkinson: quelques aspects physiopathologiques et pratique clinique. (1989) (0)
Lack of involvement of dopaminergic and GABA neurones in the inhibitory effect of harmaline on the activity of striatal cholinergic neurones in the rat (1977) (0)
A propos des méthodes neurochimiques (1976) (0)
[Athetosis or dystonia?]. (2004) (0)
Paul Bejjani In Memoriam. (2021) (0)
Judith Balkányi-Lepintre (1912-1982): first woman neurosurgeon, first woman war neurosurgeon, and first woman pediatric neurosurgeon in France. (2021) (0)
[History of the brain and neuroscience: Historical landmarks (19th-20th centuries). A general introduction]. (2021) (0)
Freezing of gait (FOG) in Parkinson’s disease patients—the contribution of Garcin and Melaragno (2021) (0)
Progress in the neurosciences and the training of medical students. (2018) (0)
Movement Disorders, the journal, and movement disorders, the field? (2011) (0)

This paper list is powered by the following services:

Other Resources About Yves Agid

en.wikipedia.org

What Schools Are Affiliated With Yves Agid?

Yves Agid is affiliated with the following schools:

Image Attributions

Image Source for Yves Agid